Business Description
Charles River Laboratories International Inc
NAICS : 541714
SIC : 8732
ISIN : US1598641074
Description
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.07 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.95 | |||||
| Debt-to-EBITDA | 2.93 | |||||
| Interest Coverage | 5.6 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.59 | |||||
| Beneish M-Score | -2.56 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 13.7 | |||||
| 3-Year EBITDA Growth Rate | 19.3 | |||||
| 3-Year EPS without NRI Growth Rate | 23.2 | |||||
| 3-Year FCF Growth Rate | -5.7 | |||||
| 3-Year Book Growth Rate | 20.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 10.05 | |||||
| Future 3-5Y Total Revenue Growth Rate | 6.17 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.7 | |||||
| 9-Day RSI | 40.38 | |||||
| 14-Day RSI | 43.47 | |||||
| 6-1 Month Momentum % | 2 | |||||
| 12-1 Month Momentum % | 8.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.49 | |||||
| Quick Ratio | 1.21 | |||||
| Cash Ratio | 0.2 | |||||
| Days Inventory | 36.66 | |||||
| Days Sales Outstanding | 50.38 | |||||
| Days Payable | 23.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.3 | |||||
| Shareholder Yield % | -0.22 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 36.99 | |||||
| Operating Margin % | 15.5 | |||||
| Net Margin % | 11.58 | |||||
| ROE % | 16.56 | |||||
| ROA % | 6.37 | |||||
| ROIC % | 7.25 | |||||
| ROC (Joel Greenblatt) % | 39.46 | |||||
| ROCE % | 11.32 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 20.95 | |||||
| Forward PE Ratio | 16.78 | |||||
| PE Ratio without NRI | 20.95 | |||||
| Shiller PE Ratio | 33.83 | |||||
| Price-to-Owner-Earnings | 23.77 | |||||
| PEG Ratio | 1.32 | |||||
| PS Ratio | 2.45 | |||||
| PB Ratio | 3.11 | |||||
| Price-to-Free-Cash-Flow | 35.19 | |||||
| Price-to-Operating-Cash-Flow | 16.3 | |||||
| EV-to-EBIT | 17.64 | |||||
| EV-to-Forward-EBIT | 14.53 | |||||
| EV-to-EBITDA | 12.49 | |||||
| EV-to-Forward-EBITDA | 12.06 | |||||
| EV-to-Revenue | 3.14 | |||||
| EV-to-Forward-Revenue | 3.02 | |||||
| EV-to-FCF | 45.32 | |||||
| Price-to-Projected-FCF | 1.32 | |||||
| Price-to-DCF (Earnings Based) | 0.85 | |||||
| Price-to-DCF (FCF Based) | 2.31 | |||||
| Price-to-Median-PS-Value | 0.87 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.21 | |||||
| Earnings Yield (Greenblatt) % | 5.67 | |||||
| Forward Rate of Return (Yacktman) % | 20.92 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:CRL
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Charles River Laboratories International Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4,178.31 | ||
| EPS (TTM) ($) | 9.43 | ||
| Beta | 1.25 | ||
| Volatility % | 24.91 | ||
| 14-Day RSI | 43.47 | ||
| 14-Day ATR ($) | 6.082487 | ||
| 20-Day SMA ($) | 204.6385 | ||
| 12-1 Month Momentum % | 8.33 | ||
| 52-Week Range ($) | 181.22 - 262 | ||
| Shares Outstanding (Mil) | 51.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Charles River Laboratories International Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Charles River Laboratories International Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Charles River Laboratories International Inc Frequently Asked Questions
What is Charles River Laboratories International Inc(CRL)'s stock price today?
The current price of CRL is $197.57. The 52 week high of CRL is $262.00 and 52 week low is $181.22.
When is next earnings date of Charles River Laboratories International Inc(CRL)?
The next earnings date of Charles River Laboratories International Inc(CRL) is 2023-11-02 Est..
Does Charles River Laboratories International Inc(CRL) pay dividends? If so, how much?
Charles River Laboratories International Inc(CRL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers